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Summary and Implications 
 Twenty-four calves were dehorned and treated with 
either topical flunixin meglumine formulated for systemic 
absorption or a placebo.  Biomarkers associated with pain 
were evaluated for up to 72 hour after the dehorning 
procedure.  Plasma cortisol concentrations, 90 minutes post-
dehorning, and mechanical nociception threshold at the 
control site were the only tested biomarkers where a 
significant difference was demonstrated.  No other 
differences of biomarkers between the two dehorned groups 
were observed for any time points.  Although this product is 
easy to dose and dispense, its effects on pain biomarkers 
appears to be negligible.   
 
Introduction 
 Dehorning is a common procedure performed on over 
90% of dairy farms.  The increasing awareness of animal 
welfare and pain mitigation have made the use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) common 
and desirable at the time of dehorning.   
 Recently a novel formulation of flunixin meglumine 
has been developed and approved in the European Union.  
This novel formulation is designed for topical application 
and transdermal absorption of the active ingredient.  
Currently, flunixin meglumine is the only NSAID approved 
for use in bovine in the United States.  However, it is only 
labeled for intravenous administration for pyrexia associated 
with bovine respiratory disease and endotoxic mastitis as 
well as the control of inflammation in endotoxemia. The 
objective of this research experiment was to determine the 
analgesic effects of a novel European formulation of 
flunixin meglumine intended for systemic absorption after 
topical application.   
 
Materials and Methods 
 Twenty four weaned male Holstein calves, ages 6 to 8 
weeks of age were enrolled into the study.  The calves were 
randomly assigned to one of three treatment groups of: 1) 
topical flunixin and dehorn (DH-FLU); 2) topical flunixin 
and sham dehorn (SHAM-FLU); and 3) placebo and dehorn 
(DH-PLBO).  Treated calves had tropical flunixin 
meglumine applied at the label dose of 3.33 mg/kg 
concurrently with dehorning.  The dehorning procedure 
consisted of applying an electrocautery dehorner to the horn 
tissue for 10 seconds.  Calves in the sham dehorn group had 
a cold dehorned applied to the horn tissue for 10 seconds.  
Biomarker parameters collected and analyzed included: 
infrared thermography (IRT), mechanical nociception 
threshold (MNT), plasma cortisol, and Substance P.   
 Infrared thermography images for maximum 
temperature were analyzed using commercially available 
research software (FLIR ExaminIR, Inc., North Billerica, 
MA).  Plasma cortisol and Substance P concentrations were 
determined by radioimmunoassay in the Pharmacology 
Analytical Support Team (PhAST) lab.   
 
Results and Discussion 
 There were no differences in the maximum 
temperatures (°C) detected for the IRT measurements of the 
medial canthus of the eye, dehorning site and adjacent skin 
for the DH groups.  Mean control point MNT measurements 
at 49 hours were 3.14 kgF, 3.46 kgF and 1.43 kgF for the  
DH-FLU,  Sham-FLU and DH-PLBO groups respectively 
(P = 0.0001).  No other differences of MNT were detected 
between groups for the other test sites and time points.   
 Peak plasma cortisol concentrations were reached at 20 
minutes post dehorning for the DH-FLU and DH-PLBO 
groups and 10 minutes for SHAM-FLU group.  Peak plasma 
cortisol concentrations were 32.0 ng/ml, 12.7 ng/ml, and 
28.8 ng/ml for the DH-FLU, SHAM-FLU and DH-PLBO 
groups respectively.  Cortisol concentrations were 
statistically lower for the DH-FLU group at 90 minutes post 
dehorning compared to the SHAM-FLU and DH-FLU 
group (P = 0.04).  Plasma cortisol concentrations were 6.12 
ng/ml, 7.66 ng/ml, and 9.68 ng/ml (P = 0.4066) at 2 hours 
post dehorning for the DH-FLU, SHAM-FLU, and DH-
PLBO groups respectively.  At 4 hours post dehorning, the 
concentrations were 6.36 ng/ml, 11.91 ng/ml, and 8.94 
ng/ml (P = 0.1142) for the DH-FLU, SHAM-FLU, and DH-
PLBO groups. 
 Substance P concentrations at 2 hours post dehorning 
were 27.16 pg/ml, 26.04 pg/ml, and 33.09 pg/ml for the 
DH-FLU, SHAM-FLU, and DH-PLBO groups respectively 
(P = 0.4577).  Substance P concentrations were 27.81 pg/ml, 
27.08 pg/ml, and 30.36 pg/ml for the DH-FLU, SHAM-
FLU, and DH-PLBO groups respectively (P = 0.8496) at 4 
hours post dehorning.  No differences in Substance P 
concentrations between groups were detected for all time 
points.   
 The published time to maximum drug concentration 
(Cmax) is between 2 to 4 hours post application according 
to published reports and provided drug literature.  At the 
time of Cmax, there are no differences between the groups 
for both plasma cortisol and substance P.  Based on the 
findings presented here flunixin meglumine, when given as 
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a topical solution, does not have significant effects on 
biomarkers associated with pain.  Other NSAIDs, like 
meloxicam, have been tested to be efficacious in this 
application and may be more appropriate for use.   
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